Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Mersana Therapeutics Inc. is currently navigating the prosecution process within the Biotechnology & Pharmaceuticals technology area. The portfolio shows 3 pending office actions, indicating a moderate level of active engagement with the patent office. This activity is distributed across 3 distinct examiners, suggesting that the company's innovations touch upon various sub-specialties within the broader biotechnology field.
The prosecution is further divided among 3 distinct art units. This distribution implies that the patent applications may involve diverse technical implementations or regulatory categories. Practitioners should note that this variety requires managing relationships and expectations across multiple examination groups simultaneously to ensure consistent results across the portfolio.
GODDARD, LAURA B is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. While the workload is spread out, the presence of multiple examiners and art units highlights a lack of examiner concentration. This strategy may result in varied prosecution timelines and outcomes depending on the specific practices and historical tendencies of each assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17289992 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | BUNNER, BRIDGET E | 22d |
| 18595834 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17289992 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | BUNNER, BRIDGET E | 22d |
| 18595834 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | GODDARD, LAURA B | — |
| 18319176 | B7-H4-TARGETED ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1614 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18595834 | B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | GODDARD, LAURA B | 1642 | §101§103DP | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18319176 | B7-H4-TARGETED ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER | STOICA, ELLY GERALD | 1614 | §103 | Non-Final OA | — | Pending | May 17, 2023 |
| 17289992 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | BUNNER, BRIDGET E | 1647 | §103§112 | Final Rejection | 22d | Pending | Apr 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMersana Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Laura B Goddard has the most, with 1 of Mersana Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
